Clinical data | |
---|---|
Other names | RG7314 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H24ClN5O |
Molar mass | 409.92 g·mol−1 |
3D model (JSmol) | |
| |
|
Balovaptan (INN ; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of post-traumatic stress disorder.[1]